Semin Liver Dis 2005; 25(2): 226-229
DOI: 10.1055/s-2005-871201
DIAGNOSTIC PROBLEMS IN HEPATOLOGY

Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hepatocellular Carcinoma in Type 1 Gaucher Disease: A Case Report with Review of the Literature

Ruliang Xu1 , Pramod Mistry3 , Gregg Mckenna2 , Sukru Emre2 , Thomas Schiano2 , Moueen Bu-Ghanim1 , Gabriel Levi1 , Maria Isabel Fiel1
  • 1Lillian and Henry M. Stratton- Hans Popper Department of Pathology, Division of Hepatopathology, New York, New York
  • 2Recanati-Miller Transplantation Institute, Mount Sinai Medical Center, New York, New York
  • 3Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut
Further Information

Publication History

Publication Date:
25 May 2005 (online)

Preview

Gaucher disease is a rare inborn error of metabolism but represents the most common type of lysosomal storage disease, and it is highly prevalent in the Ashkenazi Jewish population. It is an autosomal recessive disorder caused by deficiency of glucocerebrosidase, which results in accumulation of glucosyl ceramide in the lysosomes of tissue macrophages. The resulting phenotype is complex, involving hepatosplenomegaly, marrow infiltration, and diverse patterns of skeletal and pulmonary disease. The majority of patients (99%) have non-neuronopathic disease (type 1), but the brain is involved in neuronopathic types 2 and 3 of the disease. The standard of care for type 1 Gaucher disease is enzyme supplemental therapy with macrophage-targeted, recombinant glucocerebrosidase (imiglucerase).

Several reports indicate development of a variety of neoplasms including malignancies, especially hematologic, in patients with type 1 Gaucher disease.[1] As with other inborn errors of metabolism affecting the liver that lead to an increased risk of hepatocellular carcinoma (HCC), there has been speculation that Gaucher disease may increase the risk of malignancies in organs that are involved in the accumulation of the storage cells. The liver is universally involved in type 1 Gaucher disease and there are reports of the development of cirrhosis and an unusual type of fibrosis necessitating liver transplantation, although the hepatocytes, per se, do not appear to be involved in the storage process.[2] [3] Interestingly, HCC has also been reported in two patients with type 1 Gaucher disease.[4] [5] Herein, we report a third case of HCC in type 1 Gaucher disease that was managed successfully with liver transplantation and continued enzyme replacement therapy.

REFERENCES

Ruliang XuM.D. Ph.D. 

The Lillian and Henry M. Stratton- Hans Popper Department of Pathology, Mount Sinai School of Medicine

One Gustave L. Levy Place

New York, NY 10029

Email: ruliang.xu@msnyuhealth.org